The SAFEPAX drug coating provides a superior drug coating quality ahead of most contemporary first and second generation DCB coatings.

Available on: LEGFLOW DCB, RESTORE DCB & APERTO Shunt DCB

SAFEPAX provides a stable drug-coating finesse.
The safest DCB for the physician and the patient.

When invisibility equals safety!
‘Stable’ vs. ‘unstable’ DCB PTX coating.

  1. ‘SAFEPAX’ PTX coating of 0.1µm appear as safe as POBA.
  2. Other DCBs with ‘unstable’ and brittle balloon coatings,
    consisting of large 2.0µm-3.0µm (visible) PTX crystals, bear a risk
    for the physician and patients.

Microscopy of the ‘SAFEPAX’ balloon surface
showing no visible PTX particulates.
Minimizing the risk of thrombotic effect.

The ‘SAFEPAX’ technology utilizes the clinically important, nanocrystalline PTX coating. Even if PTX particulates would broke free they would be too small to cause any embolic or thrombotic effect.

Is Your DCB really the right choice?
Please inform yourself about your treatment option!

Clinically important Questions
on which DCB to use:

Does your DCB show white PTX
particulates on top of the balloon surface?


If yes, the DCB you are using may
provide an unstable balloon surface
drug coating quality.

Is there an advantage in using a DCB,
which is coated with a highly water
soluble drug excipient?


Paclitaxel, which is washed off the
balloon surface before it reaches the
lesion, may cause non desireable
systemic effects.

You certainly like to avoid any high
PTX drug wash off effect during
DCB catheter treatment.


You prefer focused drug release
at the lesion site only!

Do you want constant, reliable
clinical outcome after your DCB
treatment?

Don´t you feel safer if the DCB
you are using would not be coated
with free unprotected PTX particulates on the balloon surface?


(Caused by PTX particulates falling off the balloon surface)

Are you aware of the PTX particulate size on the balloon surface of your DCB?

No drug coating pitfalls but only high performance.
SAFEPAX provides superior patient results!

Clinically important
drug coating features:

SAFEPAX COATING INTEGRITY:
The indestructible, structural balloon coating integrity, combined with a protective drug coating finesse, does not require the use of an extra insertion tool.

SAFEPAX SAFETY:
Only the smallest PTX crystals appear safe enough to bear no risk of adverse embolic or thrombotic effects or obstructing the smaller distal vasculature. SAFEPAX ensures a high patient safety by non-visible 0.1µm smallest PTX particulates leapfrogging ahead of 2.0-3.0µm large Paclitaxel crystals on most other DCBs.

SAFEPAX PERFORMANCE:
Consistent and predictable drug delivery to the artery lesion site results in a homogenous and maximized drug absorption into the arterial tissue.

SAFEPAX PROTECTIVE BALLOON COATING:
The SAFEPAX Paclitaxel balloon surface coating cannot be wiped or fall off the balloon during catheter preparation, insertion or manipulation. SAFEPAX prevents endangerment of cathlab personnel, and guarantees a safe and predictable drug delivery to the target lesion site.

THE UNIQUE SAFEPAX INNOVATION:
The step beyond contemporary first and second generation DCB coatings which had to compromise on vulnerable balloon coating mixtures out of a high water soluble drug excipient with relatively large PTX crystals.